Mural Oncology PLC
Company Profile
Business description
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
Contact
10 Earlsfort Terrace
Dublin 2
DublinD02 T380
IRLT: +353 19058020
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
116
Stocks News & Analysis
stocks
Have the 3 biggest losers of the ASX 200 fallen too far?
stocks
Rethinking the way we invest in Aussie tech
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,883.80 | 39.20 | -0.44% |
| CAC 40 | 8,122.71 | 23.24 | 0.29% |
| DAX 40 | 23,836.79 | 68.83 | 0.29% |
| Dow JONES (US) | 47,716.42 | 289.30 | 0.61% |
| FTSE 100 | 9,720.51 | 26.58 | 0.27% |
| HKSE | 26,046.41 | 187.52 | 0.73% |
| NASDAQ | 23,365.69 | 151.00 | 0.65% |
| Nikkei 225 | 49,407.31 | 846.60 | -1.68% |
| NZX 50 Index | 13,443.04 | 46.11 | -0.34% |
| S&P 500 | 6,849.09 | 36.48 | 0.54% |
| S&P/ASX 200 | 8,583.20 | 30.90 | -0.36% |
| SSE Composite Index | 3,900.34 | 11.74 | 0.30% |